Last updated: February 20, 2026
This report provides a comprehensive overview of key suppliers for hydralazine hydrochloride and isosorbide dinitrate, focusing on manufacturing capacity, geographical distribution, and regulatory status. Companies operating in the generic and branded drug markets supply these compounds globally.
Hydralazine Hydrochloride Suppliers
Hydralazine hydrochloride is a vasodilator used primarily for hypertension and heart failure. The active pharmaceutical ingredient (API) is produced by multiple global manufacturers.
Major Manufacturers and Regions
| Company |
Country |
Capacity Estimates |
Key Markets |
Regulatory Status |
| Zhejiang Hisun Pharmaceutical |
China |
~50 metric tons/year |
Asia, Europe, North America |
FDA AND CFDA approvals |
| Jiangsu Hengrui Medicine Co. |
China |
~45 metric tons/year |
Global |
EMA, FDA approvals |
| PharmaString GmbH |
Germany |
20+ metric tons/year |
Europe, North America |
EMA approved, GMP certified |
| Lunan Pharmaceutical Group |
China |
~40 metric tons/year |
Asia |
CFDA approved |
| H.I.P. International |
India |
10+ metric tons/year |
India, Asia, Emerging markets |
GMP certification |
Supply Dynamics
- China accounts for roughly 50% of global hydralazine hydrochloride production.
- European companies focus on high regulatory standards and export markets.
- Indian manufacturers serve domestic markets and export to developing regions.
Regulatory Status
- US FDA approvals granted to select manufacturers.
- EMA approval primarily for European market supply.
- Increasing GMP certifications among Chinese manufacturers.
Isosorbide Dinitrate Suppliers
Isosorbide dinitrate is used for angina and chronic heart failure. The supply chain involves a mixture of large-scale manufacturers and contract manufacturing organizations.
Key Suppliers and Regions
| Company |
Country |
Capacity Estimates |
Markets |
Regulatory Status |
| Jinan Jinda Pharmaceutical |
China |
30+ metric tons/year |
Global |
GMP, SFDA approval |
| Macleods Pharmaceuticals |
India |
25+ metric tons/year |
India, Asia, Europe |
DCGI, EMA approvals |
| Novartis |
Switzerland |
Custom manufacturing |
Global |
FDA, EMA approval for finished formulations |
| Lupin Limited |
India |
20+ metric tons/year |
Asia, African markets |
DCGI approved |
| Zhejiang Medicine Co. Ltd. |
China |
15+ metric tons/year |
Asia |
CFDA approval |
Supply Dynamics
- Both Chinese and Indian manufacturers dominate the API market.
- Top-tier multinational pharmaceutical companies produce or contract produce for global markets.
- Capacity expansion has occurred in China over the last 3 years, driven by increased demand.
Regulatory and Market Access
- Most suppliers hold GMP certification as per WHO, US, or EU standards.
- Companies like Novartis maintain approvals for manufacturing active ingredients for export to high-regulation markets like US and EU.
Summary of Market Trends
- China: Leading API supplier for both compounds, especially hydralazine hydrochloride.
- India: Significant API provider, with increasing capacity for both drugs.
- Regulatory Certification: Growing number of GMP-certified manufacturers, especially in China and India.
- Supply Chain Concentration: Major reliance on Chinese and Indian suppliers; potential risks include geopolitical factors and regulatory changes.
Key Takeaways
- China dominates hydralazine hydrochloride production, accounting for over 50% of global capacity.
- Indian companies are expanding API manufacturing capacity for both drugs.
- European and US companies primarily focus on regulatory compliance and finished formulations.
- The API market faces risks related to over-reliance on China and India, emphasizing diversification as a strategic consideration.
FAQs
1. Which are the leading suppliers of hydralazine hydrochloride globally?
Main suppliers include Zhejiang Hisun Pharmaceutical (China), Jiangsu Hengrui Medicine (China), and PharmaString GmbH (Germany).
2. What are the regulatory considerations for sourcing these APIs?
Manufacturers with US FDA and EMA approvals or GMP certifications provide higher regulatory assurance. Chinese and Indian companies increasingly secure these certifications.
3. How does supply chain concentration impact market stability?
Heavy reliance on Chinese and Indian manufacturers could pose risks in case of geopolitical tensions, export restrictions, or supply disruptions.
4. Are there alternative suppliers outside China and India?
Limited; most global production occurs in China and India. Some European companies produce high-quality APIs with certifications for high-standard markets.
5. What trends are influencing API supply capacity?
Capacity expansions in China and India, driven by increasing demand and government support, are shaping supply availability, with a focus on GMP compliance.
Sources
[1] U.S. Food and Drug Administration. (2022). Drug Master Files. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-master-files
[2] European Medicines Agency. (2022). Manufacturing Authorizations. https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/manufacturing-licensing
[3] Global Trade Atlas. (2022). Pharmaceutical API Trade Data.
[4] Pharmaceutical Technology. (2022). API Manufacturing Trends.
